Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Rituximab Plus Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

Next Previous
X
Search
Trial Profile

Phase II Trial of Rituximab Plus Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Marginal zone B-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 08 Mar 2015 Planned End Date changed from 1 Feb 2015 to 1 Jun 2015, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top